GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Passage Bio Inc (NAS:PASG) » Definitions » Cyclically Adjusted Revenue per Share

Passage Bio (Passage Bio) Cyclically Adjusted Revenue per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Passage Bio Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Passage Bio's adjusted revenue per share data for the fiscal year that ended in Dec. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-09), Passage Bio's current stock price is $ 1.185. Passage Bio's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2023 was $0.00. Passage Bio's Cyclically Adjusted PS Ratio of today is .


Passage Bio Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Passage Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Passage Bio Cyclically Adjusted Revenue per Share Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial - - - - -

Passage Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Passage Bio's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Passage Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Passage Bio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Passage Bio's Cyclically Adjusted PS Ratio falls into.



Passage Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Passage Bio's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Passage Bio does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate it.


Passage Bio  (NAS:PASG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Passage Bio Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Passage Bio's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Passage Bio (Passage Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Passage Bio Inc (NAS:PASG) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Executives
Kathleen Borthwick officer: SVP, Interim CFO C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Simona King officer: Chief Financial Officer C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Dolan Sondhi director C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alexandros Fotopoulos officer: Chief Technical Officer TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Sandip Kapadia director 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
William Chou director, officer: Chief Executive Officer C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Monika Maria Toernsen officer: Chief Commercial Officer ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Mark S Forman officer: Chief Medical Officer C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Bruce A Goldsmith director, officer: CEO and President C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brian Burkavage officer: Controller C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Derrell Porter director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341